FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.10  |  FHIR Version n/a  User: [n/a]

40504911000001103: Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 16-Mar 2022. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
2190571000001110 Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
2190581000001112 Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Is a Fluticasone propionate 250micrograms/dose / Salmeterol 50micrograms/dose dry powder inhaler true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Is a Sereflo Ciphaler true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has specific active ingredient Salmeterol xinafoate true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) VMP prescribing status (attribute) Caution - AMP level prescribing advised true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has specific active ingredient Fluticasone propionate true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Salmeterol true Inferred relationship Existential restriction modifier
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Has dispensed dose form Conventional release powder for inhalation true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) 60 dose Has AMP True Sereflo Ciphaler 50micrograms/dose / 250micrograms/dose dry powder inhaler (Cipla EU Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start